RxSight (RXST) Current Deferred Revenue (2025 - 2026)
RxSight's (RXST) quarterly Current Deferred Revenue came in at $6.9 million in Q2 2026, up 110.97% on a YoY basis from $3.3 million in Q2 2025, and up 110.97% quarter-over-quarter from $3.3 million in Q4 2025.
Powered by 
Analysis
RxSight (RXST) Current Deferred Revenue (2025 - 2026) Analysis & Trends
RxSight (RXST) has reported Current Deferred Revenue for 2 consecutive years, with $6.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Deferred Revenue rose 110.97% year-over-year to $6.9 million; the trailing twelve-month figure through Jun 2026 stood at $6.9 million (up 110.97% YoY), and the FY2025 full-year result was $3.3 million, changed N/A from the prior year.
- Current Deferred Revenue grew to $6.9 million in Q2 2026 per RXST's latest filing, from $3.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $6.9 million in Q2 2026 and bottomed at $3.3 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | RxSight | 265.13 Mn | -139.12 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.88 Mn |
| Dec 31, 2025 | 3.26 Mn |
| Jun 30, 2025 | 3.26 Mn |